A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases
Phase of Trial: Phase II
Latest Information Update: 03 Dec 2019
Price : $35 *
At a glance
- Drugs Rivoceranib (Primary) ; Docetaxel; Zoledronic acid
- Indications Bone metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 14 Jan 2018 Status changed from not yet recruiting to recruiting.
- 04 May 2017 Planned initiation date changed from 1 Apr 2017 to 1 May 2017.
- 27 Apr 2017 New trial record